There were many studies, articles and books Dr. Dressler and Dr. Ettinger used when writing The Dog Cancer Survival Guide. Here is a list of the most important references about the use of lymphoma chemotherapy.
Please note that in vivo and clinical use citations were included whenever possible. We have also include links to the papers, where available. Most of the papers are found on the National Institute of Health’s online library, PubMed.
Systemic therapy of cutaneous T-cell lymphoma (Mycosis fungoides and the Sezary Syndrome). Bunn PA, Hoffman SJ, Norris D, et al. Ann Intern Med 121:592-602, 1994.
Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Bergman PJ, Ogilvie GK, Powers BE. J Vet Intern Med 10:354, 1996.
Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. Carter RF, Harris CK, Withrow SJ. J Am Anim Hosp Assoc 23:221, 1987.
Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone. Cotter SM, Goldstein MA. J Am Anim Hosp Assoc 19:159, 1983.
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Garrett LD, Thamm DH, Chun R, et al. J Vet Intern Med 16:704, 2002.
Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. Jeffreys AB, Knapp DW, Carlton WW, et al. J Am Anim Hosp Assoc 41:221, 2005.
Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? MacDonald VS, Thamm DH, Kurzman ID, et al. J Vet Intern Med 19:732, 2005
Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Moore AS, Cotter SM, Rand WM, et al. J Vet Intern Med 15:348, 2001.
Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. Valerius KD, Ogilvie GK, Fettman MJ, et al. J Am Vet Med Assoc 214:353, 1999.
The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Moore AS, Leveille CR, Reimann KA, et al. Cancer Invest 13:475, 1995.
Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Mealey KL, Northrup NC, Bentjen SA. J Am Vet Med Assoc 223:1453, 1434, 2003.
Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol. Vaughan A, Johnson JL, Williams, LE. J Vet Intern Med, 21: 1332–1339, 2007.
CCNU in the treatment of canine epitheliotropic lymphoma. Williams LE, Rassnick KM, Power HT, et al. J Vet Intern Med 20:136, 2006.
There is a whole team of dog lovers behind Dog Cancer Vet and DogCancerBlog.com, and we’re here to help, because we understand what it’s like to deal with dog cancer. We work for Maui Media, the book publisher which includes paperback and digital copies of the best-selling animal health book Dog Cancer Survival Guide: Full Spectrum Treatments to Optimize Your Dog’s Life Quality and Longevity. This must-read book is available everywhere books are sold in paperback, and digital formats (iPad, Kindle, Nook). It is authored by our veterinarian bloggers Dr. Demian Dressler, and Dr. Susan Ettinger, DVM, ACVIM (Oncology).